ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ATNM Actinium Pharmaceuticals Inc

7.94
0.00 (0.00%)
Pre Market
Last Updated: 04:01:06
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Actinium Pharmaceuticals Inc ATNM AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 7.94 04:01:06
Open Price Low Price High Price Close Price Prev Close
7.94
more quote information »

Recent News

Date Time Source Heading
3/27/202410:52IHNWFeaturedPOET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks
3/26/202407:18PRNUSActinium Announces Clinical Trial to Study Iomab-ACT..
3/11/202407:30PRNUSActinium Pharmaceuticals Launches Actinium-225 Focused..
2/26/202407:30PRNUSActinium Announces Iomab-B Markedly Increases Long Term..
2/23/202407:30PRNUSActinium Highlights Improved Survival with Iomab-B in TP53..
2/09/202416:30EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/06/202400:15EDGAR2Form EFFECT - Notice of Effectiveness
2/02/202417:03EDGAR2Form S-3/A - Registration statement under Securities Act of..
1/02/202407:30PRNUSActinium Announces Acceptance of Five Abstracts for..
12/29/202317:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/29/202317:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/29/202317:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/29/202317:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/29/202317:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202308:15PRNUSActinium Announces Iomab-B Produces High Response Rates and..
12/11/202307:45PRNUSActinium's Four Presentations at ASH Highlight the Positive..
12/08/202308:00PRNUSActinium to Highlight Broad Potential of Targeted..
12/01/202317:00EDGAR2Form 8-K - Current report
11/09/202317:05EDGAR2Form DEF 14A - Other definitive proxy statements
11/06/202307:30PRNUSActinium Presents Preclinical Data at SITC Demonstrating..
11/02/202316:15PRNUSActinium Pharmaceuticals to Attend Bio-Europe Munich 2023
11/02/202309:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/02/202309:05PRNUSActinium Announces Oral Presentation at ASH Annual Meeting..
10/04/202307:30PRNUSActinium Announces NIH Grant Extension to Advance Clinical..
9/27/202309:05PRNUSActinium Pharma Highlights Abstract Accepted for Poster..
9/07/202308:40PRNUSActinium Pharma Presents Survival Data from Extended..
8/31/202307:00PRNUSActinium Pharma Highlights Three Abstracts Accepted for..
8/21/202307:00PRNUSActinium Pharma Highlights Abstracts Accepted for Oral and..
8/14/202317:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/11/202309:00EDGAR2Form S-3 - Registration statement under Securities Act of..
7/24/202307:00PRNUSActinium Pharma to Present at the 2nd Annual Targeted..
6/26/202307:00PRNUSSNMMI 2023 Annual Meeting Abstract of the Year Awarded to..
6/23/202308:00PRNUSActinium Pharma Highlights Six Abstracts Accepted for Oral..
6/16/202307:00PRNUSActinium Pharma to Present at the Maxim Healthcare Virtual..
6/14/202307:00PRNUSActinium Pharma to Present at the TD Cowen..
6/12/202307:00PRNUSActinium Announces Positive Pivotal Phase 3 SIERRA Trial..
6/07/202307:00PRNUSActinium Pharma Set to Join Russell 2000® and Russell 3000®..
5/22/202307:00PRNUSActinium Pharma Announces Six Abstracts Accepted for Oral..
5/11/202311:18PRNUSActinium Pharma Announces Iomab-B SIERRA Trial Results..
5/10/202307:00PRNUSActinium Pharma to Present at Guggenheim Healthcare Talks..
4/28/202308:00PRNUSActinium Highlights Successful Administration of Targeted..
4/27/202310:36PRNUSActinium Announces Positive Pivotal Phase 3 SIERRA Trial..

Your Recent History

Delayed Upgrade Clock